10-Q: Nature's Sunshine Reports Soaring Q2 Net Income and EPS Amidst Strategic China JV Acquisition

Nature's Sunshine Products, Inc. announced a significant increase in net income and earnings per share for the second quarter and first half of 2025, driven by sales growth, improved gross margins, and favorable foreign exchange dynamics, alongside a strategic move to acquire full ownership of its China joint ventures.

Summary

• Consolidated net sales for the three months ended June 30, 2025, increased by 3.8% to $114.750 million, or 2.2% in local currencies, compared to the same period in 2024.
• Net sales for the six months ended June 30, 2025, increased by 2.9% to $227.998 million, or 3.3% in local currencies, compared to the same period in 2024.
• Gross profit for the three months ended June 30, 2025, rose by 4.3% to $82.299 million, with gross profit margin improving to 71.7% from 71.4% in the prior year.
• Operating income for the three months ended June 30, 2025, decreased by 24.2% to $4.274 million, primarily due to increased selling, general and administrative (SG&A) expenses.
• Operating income for the six months ended June 30, 2025, increased by 1.8% to $10.446 million.
• Net income for the three months ended June 30, 2025, surged by 270.9% to $5.519 million, and for the six months, it increased by 161.5% to $10.403 million.
• Diluted earnings per share attributable to common shareholders increased to $0.28 for the three months and $0.54 for the six months ended June 30, 2025, up from $0.07 and $0.19 respectively in the prior year.
• Foreign exchange gains significantly contributed to other income, with a net gain of $3.026 million for the quarter and $3.779 million for the six months, compared to losses in the prior year periods.
• The effective income tax rate decreased to 26.8% for the quarter and 29.0% for the six months ended June 30, 2025, compared to 66.4% and 56.2% respectively in 2024, primarily due to a decrease in foreign losses and favorable adjustments to deferred tax assets.
• Cash provided by operating activities for the six months ended June 30, 2025, increased to $6.949 million from $3.495 million in the prior year.
• The company entered into agreements to purchase Fosun Industrial's interests in its two China joint ventures for cash consideration of $3.9 million and $3.1 million, aiming for sole ownership.
• The share repurchase program was amended on May 6, 2025, allowing for an additional $25.0 million in common share repurchases, with $21.4 million remaining available as of June 30, 2025.
• Repurchased 1,011,000 shares of common stock for $12.4 million during the six months ended June 30, 2025, including 833,000 shares purchased from Fosun Pharma on June 27, 2025.

Sentiment

Score: 7

Explanation: The company reported strong net income and EPS growth, driven by sales increases, improved gross margins, and significant foreign exchange gains. Strategic moves like the China JV acquisition and expanded share repurchase program are positive. While Q2 operating income saw a decline due to increased SG&A, the overall financial performance and strategic direction indicate a positive trajectory, despite ongoing macroeconomic and geopolitical risks.

Positives

• Net income attributable to common shareholders increased by 270.9% for the quarter and 161.5% for the six months ended June 30, 2025.
• Diluted earnings per share significantly improved to $0.28 for the quarter and $0.54 for the six months.
• Consolidated net sales grew by 3.8% for the quarter and 2.9% for the six months, with positive local currency growth in most segments.
• Gross profit margin slightly improved to 71.7% for the quarter and 71.9% for the six months, driven by cost savings initiatives.
• Strong foreign exchange gains contributed significantly to other income, turning prior-year losses into substantial gains.
• Effective income tax rate decreased significantly, boosting net income.
• Cash provided by operating activities more than doubled for the six-month period, indicating improved operational cash generation.
• Strategic acquisition of Fosun Pharma's interests in China joint ventures will result in sole ownership, streamlining operations and potentially enhancing control.
• Expansion of the share repurchase program by an additional $25.0 million demonstrates management's confidence and commitment to shareholder returns.

Negatives

• Operating income for the three months ended June 30, 2025, decreased by 24.2% compared to the prior year, primarily due to increased selling, general and administrative expenses.
• Selling, general and administrative expenses increased by 13.2% for the quarter and 6.2% for the six months, attributed to compensation costs, digital marketing investments, and non-recurring expenses.
• Net sales in South Korea decreased by 6.8% (4.5% in local currency) for the quarter and 7.0% (1.8% in local currency) for the six months due to challenging macroeconomic factors.
• Net sales in China were flat for the quarter and down 3.4% for the six months (0.1% and 2.8% in local currency, respectively) due to challenging macroeconomic factors.
• Latin America and Other net sales decreased by 4.6% for the six months ended June 30, 2025, impacted unfavorably by foreign currency fluctuations.

Risks

• Extensive government regulations, including trade restrictions and export controls, can impact products, business practices, and manufacturing activities.
• Difficulty or increased cost of importing products into foreign markets and challenges in product registration for sale in foreign markets.
• Legal challenges to the direct selling program or the classification of independent consultants.
• Laws and regulations regarding direct selling may prohibit or restrict the ability to sell products in some markets or require business model changes.
• Liabilities and obligations arising from improper activity by independent consultants.
• Product liability claims could adversely affect the business.
• Impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act.
• Ability to attract and retain independent consultants, and the potential loss of key independent consultants with significant sales networks.
• Fluctuating foreign exchange rates can materially affect sales and costs.
• Failure of independent consultants to comply with advertising laws.
• Changes to independent consultants' compensation plans.
• Geopolitical issues and conflicts, such as the ongoing conflict in Eastern Europe, and changes to U.S. trade policy resulting in new or additional tariffs.
• Negative consequences from difficult economic conditions, including liquidity availability or customer willingness to purchase products.
• Risks associated with the manufacturing of products, including supply chain disruptions, manufacturing interruptions or delays, or failure to accurately forecast customer demand.
• Uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto.
• Changes in tax laws, treaties or regulations, or their interpretation.
• Failure to maintain an effective system of internal controls over financial reporting.
• Cybersecurity threats and exposure to data loss.
• Complex and evolving privacy and data protection laws and regulations regarding the storage, processing, and use of data.
• Reliance on information technology infrastructure.
• Sufficiency of trademarks and other intellectual property rights.
• Ongoing internal investigation regarding past compliance with U.S. trade controls and voluntary disclosures to BIS and OFAC, which may result in fines or penalties, though not expected to be material.
• Changes in U.S. trade policy, including tariffs, could increase costs of materials and finished goods, disrupt supply chains, or reduce demand for products.

Future Outlook

The company expects foreign markets with functional currencies other than the U.S. Dollar to continue representing a substantial portion of overall sales and operating expenses, implying continued exposure to foreign currency fluctuations. Management anticipates that higher tariffs will impact costs in 2025 but does not expect the impact to be material. The company believes that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund normal operating needs, including capital expenditures and digital investments, on both a shortand long-term basis.

Management Comments

• "In the second quarter of 2025, we experienced an increase in our consolidated net sales of 3.8 percent (or 2.2 percent in local currencies) compared to the same period in 2024."
• "The decrease in cost of sales percentage is primarily due to cost savings initiatives, partially offset by unfavorable foreign exchange and market mix."
• "The increase [in SG&A] was primarily related to the timing of compensation costs, incremental investment in digital marketing and other non-recurring expenses."
• "We expect that [the conflict in Eastern Europe] will continue to impact our business for the foreseeable future."
• "While we expect higher tariffs to impact our costs in 2025, we do not expect the impact to be material."
• "Like many other companies, we are facing significant inflationary pressures in the global economy. Our operations have been, and may continue to be, adversely impacted by inflation, primarily from higher costs of raw materials, labor, production, distribution and transportation costs."
• "We believe future payments related to [legal] matters could range from $0 to approximately $2.8 million."
• "We believe future payments related to [non-income tax] matters could range from $0 to approximately $2.9 million."
• "Management is not aware of any such changes [in tax laws and rates] that would have a material effect on our results of operations, cash flows or financial position."

Industry Context

The company operates in the natural health and wellness industry, primarily through direct selling. It faces common industry challenges such as extensive government regulations, the need to attract and retain independent consultants, and global macroeconomic factors like inflation and fluctuating foreign exchange rates. The ongoing geopolitical conflict in Eastern Europe continues to impact its operations in that region. The company is also navigating evolving U.S. trade policies and tariffs, which are affecting costs across the industry.

Legal Proceedings

• The company is a party to various legal proceedings and disputes in the United States and foreign jurisdictions, with accrued liabilities of $0.7 million as of June 30, 2025, related to estimated outcomes.
• Future payments related to other litigation where a loss is reasonably possible but not probable, or cannot be estimated, could range from $0 to approximately $2.8 million.
• The company is undergoing an internal investigation regarding past compliance with U.S. trade controls, with voluntary disclosures made to BIS (November 2024) and OFAC (April 2025). Potential violations represented less than one percent of net revenue in the last three fiscal years, and any fines or penalties are not expected to be material.

Related Party Transactions

• On June 27, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), through one of its affiliates, sold 2,854,607 shares of the Company’s common stock, resulting in Fosun Pharma ceasing to own at least 5% of the outstanding shares.
• On June 30, 2025, the Company entered into share purchase agreements with Fosun Industrial Co., Ltd. (an affiliate of Fosun Pharma) to purchase Fosun Industrial’s interest in the Company's two joint ventures, Natures Sunshine Hong Kong Limited and Shanghai Natures Sunshine Health Products Co., Ltd., for cash consideration of $3.9 million and $3.1 million, respectively.
• On June 27, 2025, the company purchased 833,000 shares of its common stock from Fosun Pharma under the share repurchase program.

Stakeholder Impact

• Shareholders benefit from increased net income and EPS, the expanded share repurchase program, and the strategic move to gain full ownership of China joint ventures, which could enhance long-term value.
• Independent consultants are impacted by changes in volume incentives and compensation plans, as well as the company's ability to attract and retain them, which directly affects their earning potential.
• Customers may experience price changes due to inflationary pressures and tariffs, and product availability could be affected by supply chain disruptions.
• Employees are affected by compensation costs and the overall financial health and strategic direction of the company.
• Regulatory authorities are involved in the ongoing trade controls investigation and the approval process for the China joint venture acquisition.

Next Steps

• Complete the purchase of Fosun Industrial's interests in the China joint ventures, subject to customary closing conditions and regulatory approvals in the Peoples Republic of China.
• Continue to monitor the social, political, regulatory, and economic environment in Ukraine and Russia and consider further actions as appropriate.
• Evaluate the full impact of the newly signed 'One Big Beautiful Bill Act' on consolidated financial statements.
• Continue to monitor additional pressure that tariff-related price increases may have and other effects of tariffs on the business, including the price, availability, and quality of raw materials and other ingredients.
• Continue to manage inflationary pressures on raw materials, labor, production, distribution, and transportation costs.

Key Dates

Recommendation

The company reported a substantial increase in net income and diluted EPS for both the quarter and six-month period, driven by sales growth, improved gross margins, favorable foreign exchange gains, and a lower effective tax rate. Strategic moves, such as gaining sole ownership of the China joint ventures and the expanded share repurchase program, enhance long-term value and demonstrate confidence in future performance. While operating income for the quarter saw a slight decline due to increased SG&A, the overall financial health and strategic direction suggest a positive outlook for investors.

Keywords

Nutritional supplements, Direct selling, Multi-level marketing, Health and wellness, Dietary supplements, Herbal products, Personal care, Weight management, International sales, SEC filing, Quarterly report, Earnings, Financial results, Share repurchase, Joint venture, China market, Foreign exchange, Supply chain, Inflation, Trade controls